Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients-Reference-Cited by-同舟云学术

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

Published:2012-10 Issue:9 Volume:107 Page:1481-1487
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Reardon D A,Herndon J E,Peters K B,Desjardins A,Coan A,Lou E,Sumrall A L,Turner S,Lipp E S,Sathornsumetee S,Rich J N,Sampson J H,Friedman A H,Boulton S T,Bigner D D,Friedman H S,Vredenburgh J J

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2012415.pdf

Reference24 articles.

1. Cohn AL, Bekaii-Saab TS, Bendell JC, Hurwitz H, Kozloff M, Roach N, Tezcan H, Feng S, Sing AP, Grothey A (2010) Clinical outcomes in bevacizumab (BV) treated patients (pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BRiTE data beyond progression (BBP). Proc Am Soc Clin Oncol 28: 284s (abstract # 3596)

2. Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14 (11): 1131–1138

3. Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE, Bailey L, Peters KB, Friedman HS, Vredenburgh JJ (2012) Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118: 1302–1312

4. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17 (5): 1516–1525

5. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27 (28): 4733–4740

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT;Clinical Cancer Research;2024-06-05

2. Bevacizumab for Glioblastoma Multiforme: A Literature Review;JAP Academy Journal;2024-06-01

3. Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial;Communications Medicine;2023-09-08

4. Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors;Scientific Reports;2023-06-09

5. Re-Irradiation Combined with Bevacizumab for Recurrent Glioblastoma beyond Bevacizumab Failure: Survival Outcomes and Prognostic Factors;2023-04-19